Macula displacement common after RRD repair

Article

Macula displacement is common after rhematogenous retinal detachment (RRD) repair and is heterogenous in nature, reveals a recent study.

Macula displacement is common after rhematogenous retinal detachment (RRD) repair and is heterogenous in nature, reveals a recent study.

A team headed by Dr Edward Lee, Department of Ophthalmology, St Thomas’ Hospital, London, UK, postoperatively investigated patients undergoing primary RRD repair using fundus autofluorescence and OCT imaging. The results were assessed for correlations with symptoms and preoperative features.

In 72% of 32 consecutive fovea-involving detachments treated with vitrectomy and gas macula displacement was evident. This was also seen in 29.4% of foveal-sparing cases treated with vitrectomy and gas and in all patients with fovea-involving cases with detachments treated by vitrectomy and oil.

The results revealed a significant correlation between the presence of macula displacement and symptoms of distortion in the early postoperative period. Patients with symptoms described bending of lines with or without objects appearing as smaller or narrower in the operated eye. The extent of displacement was linked with distance from the optic disc and the extent of retinal detachment.

The group discovered that most affected patient, who underwent RRD repair, are symptomatic in the early postoperative period.

The abstract can be found in the British Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.